Pfizer Inc. / Anacor Pharmaceuticals

Atopic Dermatitis (Eczema), mild-to-moderate

Disease Overview

Atopic dermatitis is a chronic, relapsing inflammatory skin disease driven by Th2-skewed immune dysregulation and skin-barrier dysfunction. It causes intense pruritus, eczematous lesions, sleep disruption, and reduced quality of life. Mild-to-moderate disease — the segment Eucrisa targets — is the largest patient pool but had been served almost exclusively by topical corticosteroids and topical calcineurin inhibitors prior to 2016.

Competitive Landscape

At the time of the Anacor deal (May 2016), the only non-steroidal topical options in mild-to-moderate atopic dermatitis were the topical calcineurin inhibitors Elidel (pimecrolimus) and Protopic (tacrolimus), both carrying FDA black-box warnings. Crisaborole — approved December 2016 as Eucrisa — became the first new topical mechanism (PDE-4 inhibitor) for atopic dermatitis in over a decade and the first non-steroidal option without a malignancy black box. The systemic landscape transformed shortly after: Sanofi/Regeneron's Dupixent (dupilumab, IL-4Rα antibody) was approved in March 2017 for moderate-to-severe disease, and Incyte's Opzelura (ruxolitinib, topical JAK inhibitor) followed in September 2021 with stronger efficacy in mild-to-moderate disease. By 2024, Pfizer's own oral JAK1 inhibitor Cibinqo (abrocitinib) and Lilly's Ebglyss (lebrikizumab) had crowded the moderate-to-severe segment. Pre-launch analysts projected $2B+ peak sales for crisaborole assuming $1,200/year pricing; actual sales materially undershot due to commercial-step-edit barriers and the rapid emergence of Opzelura and Dupixent. The deal repositioned Pfizer's inflammation/immunology franchise but ultimately delivered modest commercial returns relative to the $5.2B price.

Onychomycosis (Toenail Fungus)

Competitive Landscape

Onychomycosis treatment segments cleanly by administration route and antifungal MOA class, with oral systemic agents dominating on cure-rate economics. Oral allylamine (standard of care): Lamisil (terbinafine, Novartis; generic since 2007) remains first-line with approximately 70% mycologic cure at 24 weeks. Oral triazoles: Sporanox (itraconazole, Janssen; generic) is second-line for dermatophyte and non-dermatophyte species; fluconazole (generic, Diflucan) is used off-label in shorter pulsed regimens. Topical oxaborole (the Kerydin MOA class): Kerydin (tavaborole 5% topical solution, Pfizer/Anacor, FDA-approved July 2014) inhibits fungal leucyl-tRNA synthetase with 9.1% complete cure at 48 weeks in pivotal trials. Topical triazole: Jublia (efinaconazole 10% topical solution, Bausch Health/Ortho Dermatologics, approved June 2014) generated approximately $306M in 2023 Bausch Health revenue, achieving 17.8% complete cure and serving as Kerydin's primary commercial competitor. Topical hydroxypyridone: Penlac (ciclopirox 8% nail lacquer, Sanofi; generic) offers a low-cost option with modest efficacy. Device-based therapies: laser treatments (PinPointe FootLaser, Cutera Genesis Plus) are adjunctive and typically not insurance-covered. Commercial read: Kerydin lost commercial momentum to Jublia and was divested by Pfizer to Sandoz in 2019; generic tavaborole launched 2021. The topical segment is a niche specialty dermatology and podiatry market (under $500M U.S.) anchored by oral terbinafine on cost-effectiveness.

Atopic Dermatitis (Eczema)

Competitive Landscape

Atopic dermatitis has fragmented rapidly across topical and systemic MOA classes, with small-molecule and biologic entrants reshaping the stepwise treatment paradigm. Topical PDE-4 inhibitors: Eucrisa (crisaborole 2% ointment, Pfizer, FDA-approved December 2016 for mild-to-moderate AD age 3 months and older) and Zoryve (roflumilast cream 0.15%, Arcutis, AD approval July 2024) compete directly in the non-steroidal topical segment. Topical calcineurin inhibitors: Protopic (tacrolimus ointment, generic) and Elidel (pimecrolimus cream, Bausch Health) dominate the legacy non-steroid topical niche. Topical JAK inhibitor: Opzelura (ruxolitinib cream 1.5%, Incyte, approved September 2021 for mild-to-moderate AD) generated approximately $508M in 2024 Incyte revenue. Topical corticosteroids: generic triamcinolone and clobetasol dominate prescription volume. Systemic biologics: Dupixent (dupilumab IL-4Ralpha, Sanofi/Regeneron) delivered approximately $14B global 2024 sales across indications and dominates moderate-to-severe AD; Adbry/Adtralza (tralokinumab IL-13, LEO Pharma) and Ebglyss (lebrikizumab IL-13, Eli Lilly, approved September 2024) compete in the IL-13 subclass. Oral JAK inhibitors: Rinvoq (upadacitinib, AbbVie) and Cibinqo (abrocitinib, Pfizer) carry boxed warnings but deliver rapid itch control in severe disease. Commercial read: Eucrisa's topical PDE-4 niche has been disrupted by Opzelura and Zoryve on efficacy, and generic crisaborole launch exposure looms at patent expiry around 2027.

Psoriasis

Competitive Landscape

Psoriasis is a high-value biologic-dominated market with a crowded topical flank. Topical PDE-4 inhibitors: Zoryve (roflumilast cream 0.3%, Arcutis, FDA-approved July 2022 for plaque psoriasis) is the category definer; AN2898 (Pfizer/Anacor, Phase 2) was discontinued post-acquisition. Topical AhR agonists: Vtama (tapinarof cream 1%, Organon, approved May 2022) competes in the non-steroidal topical category. Systemic biologics by MOA: IL-23 inhibitors — Skyrizi (risankizumab, AbbVie) reported $11.7B in 2024 sales, Tremfya (guselkumab, J&J) and Ilumya (tildrakizumab, Sun Pharma). IL-17 inhibitors — Cosentyx (secukinumab, Novartis), Taltz (ixekizumab, Lilly), Bimzelx (bimekizumab, UCB, IL-17A/F dual, approved October 2023). TNF inhibitors — Humira (adalimumab, AbbVie, biosimilar erosion since 2023), Enbrel (etanercept, Amgen), Remicade (infliximab). Oral systemics: Otezla (apremilast PDE-4, Amgen; ~$2.2B 2024), Sotyktu (deucravacitinib TYK2, BMS, approved 2022). Topical corticosteroids and vitamin D analogs (calcipotriene generics) anchor volume. Commercial read: AN2898's discontinuation removed Pfizer from the topical psoriasis small-molecule race; Zoryve and Vtama captured the non-steroidal window.